{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20696083",
  "DateCompleted": {
    "Year": "2010",
    "Month": "09",
    "Day": "20"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "18"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2010",
        "Month": "08",
        "Day": "10"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1186/1465-9921-11-108"
    ],
    "Journal": {
      "ISSN": "1465-993X",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "1",
        "PubDate": {
          "Year": "2010",
          "Month": "Aug",
          "Day": "10"
        }
      },
      "Title": "Respiratory research",
      "ISOAbbreviation": "Respir Res"
    },
    "ArticleTitle": "Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold.",
    "Pagination": {
      "StartPage": "108",
      "MedlinePgn": "108"
    },
    "Abstract": {
      "AbstractText": [
        "The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms.",
        "In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo.",
        "Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1alpha, IP-10, IL-10, and IFN-alpha2 were reduced in the Iota-Carrageenan group.",
        "Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Larger trials are indicated to confirm the results."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Marinomed Biotechnologie GmbH, Veterinaerplatz 1, Vienna, Austria."
          }
        ],
        "LastName": "Eccles",
        "ForeName": "Ron",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Meier",
        "ForeName": "Christiane",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Jawad",
        "ForeName": "Martez",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Weinm\u00fcllner",
        "ForeName": "Regina",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Grassauer",
        "ForeName": "Andreas",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Prieschl-Grassauer",
        "ForeName": "Eva",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Respir Res",
    "NlmUniqueID": "101090633",
    "ISSNLinking": "1465-9921"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Aerosols"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Inflammation Mediators"
    },
    {
      "RegistryNumber": "9000-07-1",
      "NameOfSubstance": "Carrageenan"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Inhalation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aerosols"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Carrageenan"
    },
    {
      "QualifierName": [
        "drug therapy",
        "immunology",
        "virology"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Inflammation Mediators"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "immunology",
        "virology"
      ],
      "DescriptorName": "Nasal Lavage Fluid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Viral Load"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ]
}